Indivior PLC (INDV) Q3 2024 Earnings Call Transcript Summary
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript Summary
Gross margin stood at 82%, though this marked a sequential and year-over-year decline due to cost inflation.The following is a summary of the Indivior PLC (INDV) Q3 2024 Earnings Call Transcript:
以下是Indivior PLC（INDV）2024年第三季度業績會文本摘要：
Financial Performance:
金融業績：
Indivior PLC reported a 13% increase in Q3 net revenue to $307 million.
Adjusted operating profit rose by 62% to $97 million.
Gross margin stood at 82%, though this marked a sequential and year-over-year decline due to cost inflation.
SUBLOCADE's net revenue for the quarter was $191 million, up 14% from the previous year.
Indivior PLC報告第三季度淨營業收入增長13%，達30700萬美元。
調整後的營業利潤增長62%，達9700萬美元。
儘管毛利率爲82%，但由於成本通脹，這標誌着順序和同比下降。
本季度SUBLOCADE的淨營業收入爲19100萬美元，比去年同期增長14%。
Business Progress:
業務進展：
SUBLOCADE U.S. patients and treatment grew 37% year-over-year to 166,600.
The number of active dispensing HCPs for SUBLOCADE increased by 15% to over 7,700.
Indivior added one new partner, bringing the total number of alternate injection sites to about 1,220.
Indivior is focusing on streamlining actions targeting cost reduction in G&A and reprioritizing the R&D pipeline.
SUBLOCADE美國患者和治療服務同比增長37%，達到166,600人。
SUBLOCADE活躍開藥保健提供者數量增加了15%，超過了7,700人。
Indivior新增了一個新夥伴，將備用注射地點的總數增至約1,220個。
Indivior正在專注於簡化行動，重點是降低管理費用和重新安排研發管線。
Opportunities:
機會：
Established approximately 180 experiential programs for OPVEE and 32 states now have standing orders in place.
Indivior confirmed a 10-year contract with BARDA involving net revenue from two orders within the quarter.
爲OPVEE設立了約180個體驗項目，目前有32個州已經建立了預約訂單。
Indivior確認了與BARDA的爲期10年的合同，涉及本季度兩筆訂單的淨營業收入。
Risks:
風險：
SUBLOCADE's growth being impacted by intensified initial trial and adoption of competing products, variability in funding, and further destocking in certain justice system accounts.
SUBLOCADE的增長受到加劇的初始試用和競爭產品的採用影響，資金來源的變化以及某些司法系統帳戶的進一步減庫存。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
